A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled, Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients with Postbariatric Hypoglycemia
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Exendin 9 (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- Acronyms PREVENT
- 09 Nov 2017 According to an Eiger BioPharmaceuticals media release, the company expects to initiate this study in 4Q 2017 and trial completion is anticipated in 2H 2018.
- 07 Dec 2016 New trial record
- 29 Nov 2016 According to an Eiger BioPharmaceuticals media release, company has filed an investigational new drug (IND) application with the FDA.